$HALB ~ Based on the promising results seen with this proprietary monoclonal antibody, Halberd Corporation now plans to test the ability of the antibody in blocking the infection of cells and replication of the COVID-19 virus in additional studies. This would demonstrate its potential therapeutic value in preventing damage to vital organs.

https://finance.yahoo.com/news/halberd-corp-r...00488.html